AMPH - CIK 0001297184
The table below shows Amphastar Pharmaceuticals, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | $47.84M | $35.08M | $55.29M | $40.38M | $50.77M | $22.82M |
| Capital expenditure | $9.51M | $10.70M | $8.79M | $9.48M | $6.14M | $7.62M |
| Investing cash flow | -$16.73M | $10.48M | $15.24M | -$6.33M | -$9.11M | -$8.70M |
| Dividends paid | - | - | - | - | - |
Amphastar Pharmaceuticals, Inc. reported operating cash flow of $156.12M for fiscal year 2025. That is down 26.8% from $213.39M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from $38.56M (FY 2016) to $156.12M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | $29.49M | $11.00M | - | $8.02M | $1.23M | $3.78M |
| Financing cash flow | -$30.21M | -$14.50M | -$13.58M | -$13.55M | $4.65M | -$6.64M |